Drugs for Coagulation Disorders

Slides:



Advertisements
Similar presentations
Chapter 19 Hematologic Products.
Advertisements

Drugs for Coagulation Disorders Andrew N. Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University October 8, 2008
Chapter 19 Agents Affecting Blood Clotting. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Blood.
Anticoagulant, Antiplatelet, and Thrombolytic Drugs
Warfarin Sodium (Anticoagulant) Therapy Training 03/10/2015.
ANAESTHESIA AND ANTICOAGULANTS
Vascular Pharmacology
Anti-platelet drugs Dr. Ishfaq Bukhari Dec
PTP 546 Module 6 Cardiovascular Pharmacology: Part II Jayne Hansche Lobert, MS, RN, ACNS-BC, NP 1Lobert.
Week 7: Fibrinolysis and Thrombophilia Secondary fibrinolysis Secondary fibrinolysis Primary fibrinolysis Primary fibrinolysis Plasminogen Plasminogen.
Dr MOHAMMED H SAIEMALDAHR FACULTY of Applied Medical Sciences
Anticoagulation in the Acute Care Population Aimee Ring PT, DPT, GCS.
Lecture NO- 12- Dr: Dalia Kamal Eldien.  Coagulation: Is the process by which blood changes from a liquid to a clot. Coagulation begins after an injury.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 28 Coagulation Modifier Drugs.
Agents Affecting Blood Clotting. Anticoagulant Agents Prevent the extension and formation of clots. Inhibition by interference with the ‘coagulation cascade’
NURS 1950 Pharmacology I 1.  Objective 1: identify general reasons anticoagulants are given 2.
BY :DR. ISRAA OMAR.  It is initiated concomitantly with coagulation cascade, resulting in the formation of active plasmin,which digest fibrin.  The.
Anticoagulant, Antiplatelet, and Thrombolytic Drugs
ANTICOAGULANT, THROMBOLYTICS & ANTIPLATELET DRUGS.
Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
Drugs for Coagulation disorders. There are a number of different categories of drugs which modify the coagulation process: I. Anticoagulants II. Antiplatelet.
Hemostasis. Hemostasis Definition Prevention of blood loss (stoppage of blood flow)
Thrombolytic drugs BY :DR. ISRAA OMAR.
CARDIOVASCULAR MODULE: DEEP VENOUS THROMBOSIS THROMBOPHLEBITIS Adult Medical-Surgical Nursing.
ANTIPLATELET DRUGS.
BY :DR. ISRAA OMAR.  It is initiated concomitantly with coagulation cascade, resulting in the formation of active plasmin,which digest fibrin.  The.
Developed by: Dawn Johnson, RN, MSN, Ed.  Internally and externally  Prevent bleeding from wounds which could lead to shock or even death.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 27 Coagulation Modifier Drugs.
Pulmonary Embolism Pulmonary embolism is blockage in one or more arteries in your lungs. Maggie Trainor.
Anticoagulations and Coagulants
Drugs Used to Treat Thromboembolic Disorders Chapter 27 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Fibrinolytics, anticoagulants and antiplatelets
ANTIPLATELET DRUGS Learning objectives By the end of this lecture, students should be able to: - describe different classes of anti-platelet drugs and.
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to to describe different classes of anti-platelet.
Antiplatelet drugs Dr.V.V.Gouripur. Antiplatelet drug An antiplatelet drug is a member of a class of drugs that decreases platelet aggregation and inhibits.
Lots of clots Dr Tom Mabin Vergelegen Mediclinic Somerset West October 16th 2015 Helderberg Cardiac Support Group Seminar.
Blood coagulation is a complex process that involves vasoconstriction, platelet clumping or aggregation, and a cascade of clotting factors produced in.
ALTERATIONS IN THE NERVOUS SYSTEM
Agents Affecting Blood Clotting
Deep Vein Thrombosis (DVT)
Coagulation Modifier Agents Lilley Pharmacology Text: Chapter 26 Original Text modified by: Anita A. Kovalsky, R.N., M.N.Ed. Professor of Nursing Original.
Chapter 19 Agents affecting Blood Clotting. Blood Clotting p461 Clotting is necessary to prevent fatal loss of blood from a minor injury Thromboemboli.
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to To describe the role of platelets in.
DVT cases.  Heparin, low molecular weight heparin, or fondaparinux are usually continued for at least five days, along with another medication called.
Prof. Abdulrahman Almotrefi
Hemostasis and Coagulation Hemostasis Hemostasis is the maintenance of circulating blood in the liquid state and retention of blood in the vascular system.
Anticoagulants, Antiplatelets, and Thrombolytics
Hemostasis Is a complex process which causes the bleeding process to stop. It refers to the process of keeping blood within a damaged blood vessel. Dependent.
Anticoagulants Course: Pharmacology I Course Code: PHR 213 Course Instructor: Sabiha Chowdhury Lecturer Department of Pharmacy BRAC University.
Bleeding Tendency Dr. Mervat Khorshied Ass. Prof. of Clinical and Chemical Pathology.
Drugs Used in Coagulation Disorders
Anticoagulant, Antiplatelet, and Thrombolytic Drugs.
II. Antiplatelet Drugs.
Chapter 23 Thrombo-Embolic diseases
23 Anticoagulants.
Bleeding disorders Deficiency of any of the clotting factors leads to excessive bleeding Most common and important bleeding disorders are due Vitamin K.
Blood/Blood Formation
Med Chem Tutoring for Anticoagulants, Antiplatelets, and Thrombolytics
The normal haemostasis process involves three stages: 1
The pathology of cardiovascular disease (CVD)
Coagulation Modifier Drugs
Coagulation Disorders
ANTICOAGULANTS Dr. A. Shyam Sundar. M.Pharm., Ph.D,
23 Anticoagulants.
Drugs Affecting Blood.
Anticoagulants.
Antiplatelet Drugs Dr. : Asmaa Fady MD., MSC, M.B, B.Ch
FIBRINOLYTIC DRUGS VIJAYA LECHIMI RAJ.
Presentation transcript:

Drugs for Coagulation Disorders 20 Drugs for Coagulation Disorders

Learning Outcomes Explain the importance of hemostasis. Construct a flow chart diagramming the important steps of hemostasis and fibrinolysis. Describe the types of disorders for which coagulation modifier drugs are prescribed. Identify the primary mechanisms by which coagulation modifier drugs act.

Learning Outcomes For each of the classes in the Drug Snapshot, identify representative drugs, explain their mechanisms of action, primary actions, and important adverse effects. Categorize coagulation modifier drugs based on their classifications and mechanisms of action.

Core Concept 20.1 Hemostasis is a complex process involving multiple steps and many clotting factors. Hemostasis is the balance between clot formation and clot breakdown

Coagulation Everyone is familiar with simple cuts and scraps and we all take for granted that they will stop bleeding in a few minutes.

Basic steps in hemostasis

Major steps in the coagulation cascade

Coagulation Cascade This process normally takes about 6 minutes Vitamin K is required for the liver to produce these clotting factors Liver disease can greatly effect coagulation

Removing a blood clot is essential to restoring normal circulation. Core Concept 20.2 Removing a blood clot is essential to restoring normal circulation.

Primary steps in fibrinolysis

Fibrinolysis

Clots Once a stationary clot forms (thrombus), it often grows larger as more fibrin is added. Pieces of the clot may break off and travel in the blood stream to possibly lodge elsewhere. A traveling clot is know as an embolus When clots or emboli form, drug therapy becomes necessary.

Deep Vein Thrombosis/Embolus

Drugs are used to modify the coagulation process. Core Concept 20.3 Drugs are used to modify the coagulation process.

Drugs Anticoagulants used to prevent the formation of clots Inhibit specific clotting factors in the coagulation cascade or diminish the clotting action of platelets Increase the normal time the body takes to form clots

“Blood Thinners” This is an incorrect term; However, it is commonly used. The drugs do not change the thickness of the blood, just inhibits the clotting cascade

Drugs Thrombolytics used to dissolve such life-threatening clots. Hemostatics used to speed clot formation, or to limit bleeding from a surgical site.

Anticoagulants prevent the formation and enlargement of clots. Core Concept 20.4 Anticoagulants prevent the formation and enlargement of clots.

Anticoagulants Actions Adverse effect is bleeding. Inhibit certain clotting factors Lengthen clotting time Prevent thrombi from forming or growing larger Adverse effect is bleeding. Specific blockers administered to reverse the anticoagulant effects

Primary Anticoagulants heparin (Hep-Lock warfarin (Coumadin) Coumadin therapy can overlap heparin therapy Do not give ASA with these drugs RANDI Precautions

Antidotes: Anticoagulants Protamine sulfate is used for heparin Vitamin K is administered for warfarin.

Vitamin K Foods high in Vitamin K can reverse the action of warfarin (Coumadin) Green leafy vegetables Milk and milk products Some cereals Orange juice Cauliflower Cucumbers

Laboratory Tests Oral Anticoagulants Prothrombin time (PT) Normal range for PT is 12 to 15 seconds Prolonged with anticoagulant treatment. International Normalized Ratio (INR) Method of performing PT tests varies from laboratory to laboratory

Laboratory Tests Oral Anticoagulants This is PT multiplied by a correction factor. Recommended post-treatment INR values range from 2 to 4.5.

Mechanism of action of anticoagulants

Adverse Effects Most common and potentially serious adverse effect is bleeding. Signs: Bruising Bleeding gums Nosebleed Blood in urine or stool

Signs of Bleeding

Core Concept 20.5 Antiplatelet agents prolong bleeding time by interfering with platelet aggregation.

Antiplatelet Agents Used to prevent clot formation in arteries. Three primary subclasses of antiplatelet agents Aspirin Adenosine diphosphate (ADP) receptor blockers Glycoprotein IIb/IIIa receptor blockers.

Thrombolytics are used to dissolve existing clots. Core Concept 20.6 Thrombolytics are used to dissolve existing clots.

Thrombolytics Prescribed for disorders in which a clot has already formed, including the following: Acute MI Pulmonary embolism Cerebrovascular accident (CVA) DVT

Thrombolytics Prescribed for disorders in which a clot has already formed, including the following: Arterial thrombosis Coronary thrombosis To clear thrombi in arteriovenous cannulas and blocked IV catheters

Hemostatics are used to promote the formation of clots. Core Concept 20.7 Hemostatics are used to promote the formation of clots.